brecanavir + ritonavir

Brecanavir (GW640385) is an investigational HIV-1 protease inhibitor developed for use in combination with other antiretroviral agents. Ritonavir is a well-established HIV-1 and HIV-2 protease inhibitor that is primarily used as a pharmacokinetic booster due to its potent inhibition of the cytochrome P450 3A4 enzyme, thereby increasing plasma concentrations of co-administered protease inhibitors. The combination of brecanavir and ritonavir was studied in clinical trials for the treatment of HIV-1 infection in adults who had prior experience with protease inhibitors. Brecanavir acts by inhibiting the viral protease required for processing polyprotein precursors into functional proteins necessary for infectious virus production. Ritonavir enhances the effectiveness of brecanavir by inhibiting its metabolism and increasing its bioavailability[2][4][5][6].

Brand names

Norvir

Other names

brecanavir boosted with ritonavir